Related references
Note: Only part of the references are listed.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer
Jiao Hu et al.
THERANOSTICS (2021)
Re: Aurelie Kamoun, Aurelien de Reynies, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 2020;77:420-33 A Statement from the International Bladder Cancer Network
Stephen B. Williams et al.
EUROPEAN UROLOGY (2020)
Clinical outcome after progressing to frontline and second-line Anti-PD-1/PD-L1 in advanced urothelial cancer
Alfonso Gomez de Liano Lista et al.
EUROPEAN UROLOGY (2020)
Metabolism-associated molecular classification of hepatocellular carcinoma
Chen Yang et al.
MOLECULAR ONCOLOGY (2020)
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy
Lukas Marcelis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2020)
Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy
Markus Eckstein et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Immunotherapy in Bladder Cancer: Current Methods and Future Perspectives
Mikolaj Wolacewicz et al.
CANCERS (2020)
FIP200 Suppresses Immune Checkpoint Therapy Responses in Breast Cancers by Limiting AZI2/TBK1/IRF Signaling Independent of Its Canonical Autophagy Function
Takako Okamoto et al.
CANCER RESEARCH (2020)
Hypohidrosis as an immune-related adverse event of checkpoint inhibitor therapy
Anna E. Kersh et al.
IMMUNOTHERAPY (2020)
Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes
Alejandro Meraz-Munoz et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
Glioma-derived IL-33 orchestrates an inflammatory brain tumor microenvironment that accelerates glioma progression
Astrid De Boeck et al.
NATURE COMMUNICATIONS (2020)
Comprehensive Analysis of the PD-L1 and Immune Infiltrates of m6A RNA Methylation Regulators in Head and Neck Squamous Cell Carcinoma
Lilan Yi et al.
MOLECULAR THERAPY-NUCLEIC ACIDS (2020)
Tumor microenvironment remodeling by an engineered oncolytic adenovirus results in improved outcome from PD-L1 inhibition
Victor Cervera-Carrascon et al.
ONCOIMMUNOLOGY (2020)
Multi-Omics Profiling Reveals Distinct Microenvironment Characterization and Suggests Immune Escape Mechanisms of Triple-Negative Breast Cancer
Yi Xiao et al.
CLINICAL CANCER RESEARCH (2019)
Tumor Microenvironment Characterization in Gastric Cancer Identifies Prognostic and Immunotherapeutically Relevant Gene Signatures
Dongqiang Zeng et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer
Andrew Woolston et al.
CANCER CELL (2019)
The Stromal and Immune Landscape of Colorectal Cancer Progression during Anti-EGFR Therapy
Irene Catalano et al.
CANCER CELL (2019)
Mutation Analysis of the FGFR3-encoding gene Does Not Predict Response to Checkpoint Inhibitor Treatment in Metastatic Bladder Cancer
Nils O. Elander et al.
EUROPEAN UROLOGY (2019)
Immune Signature-Based Subtypes of Cervical Squamous Cell Carcinoma Tightly Associated with Human Papillomavirus Type 16 Expression, Molecular Features, and Clinical Outcome
Xiaofan Lu et al.
NEOPLASIA (2019)
DDR Pathway Alteration, Tumor Mutation Burden, and Cisplatin Sensitivity in Small Cell Lung Cancer: Difference Detected by Whole Exome and Targeted Gene Sequencing
Peng Luo et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Diego Chowell et al.
SCIENCE (2018)
Re: Comprehensive Molecular Characterization of Muscle-invasive Bladder Cancer
Ryoichi Saito et al.
EUROPEAN UROLOGY (2018)
Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas
Qianxing Mo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
A validation and extended description of the Lund taxonomy for urothelial carcinoma using the TCGA cohort
Nour-al-dain Marzouka et al.
SCIENTIFIC REPORTS (2018)
Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas
Qianxing Mo et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Peng Jiang et al.
NATURE MEDICINE (2018)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer
Vinod P. Balachandran et al.
NATURE (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
Whijae Roh et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Immune Activation and Benefit From Avelumab in EBV-Positive Gastric Cancer
Anshuman Panda et al.
JNCI-Journal of the National Cancer Institute (2017)
Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade
Haidong Tang et al.
CANCER CELL (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
limma powers differential expression analyses for RNA-sequencing and microarray studies
Matthew E. Ritchie et al.
NUCLEIC ACIDS RESEARCH (2015)
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Jacques Ferlay et al.
INTERNATIONAL JOURNAL OF CANCER (2015)
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Woonyoung Choi et al.
CANCER CELL (2014)
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Jeffrey S. Damrauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype
Sandra Rebouissou et al.
SCIENCE TRANSLATIONAL MEDICINE (2014)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Inferring tumour purity and stromal and immune cell admixture from expression data
Kosuke Yoshihara et al.
NATURE COMMUNICATIONS (2013)
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Guangchuang Yu et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2012)
Cancer Immunoediting: Integrating Immunity's Roles in Cancer Suppression and Promotion
Robert D. Schreiber et al.
SCIENCE (2011)
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Craig H. Mermel et al.
GENOME BIOLOGY (2011)
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Matthew D. Wilkerson et al.
BIOINFORMATICS (2010)
Subclass Mapping: Identifying Common Subtypes in Independent Disease Data Sets
Yujin Hoshida et al.
PLOS ONE (2007)
A modified K-means algorithm for circular invariant clustering
D Charalampidis
IEEE TRANSACTIONS ON PATTERN ANALYSIS AND MACHINE INTELLIGENCE (2005)
Share Paper
